Stony Brook (N.Y.) Heart Institute’s Center for Advanced Lipid Management has become the first center in the world to administer plozasiran for treatment of familial chylomicronemia syndrome.
An estimated 6,500 people in the U.S. experience FCS, a condition associated with extreme triglyceride levels that can lead to severe pancreatitis, according to a Dec. 31 news release from Stony Brook Medicine.
The Center for Advanced Lipid Management at Stony Brook Heart Institute specializes in genetic and rare lipid disorders while also providing care for coronary artery disease, heart attack, stroke and peripheral arterial disease, the release said.
Leave a Reply